CytomX Therapeutics (CTMX) Tops Q3 EPS by 24c

CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of $0.07, $0.24 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $33.43 million versus the consensus estimate of $17.1 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Bruker (BRKR) files mixed shelf
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00